Single-center nonrandomized clinical trial to assess the safety and efficacy of irreversible electroporation (IRE) ablation of liver tumors in humans: Short to mid-term results

European Journal of Surgical Oncology

Volumn 43, Issue 4, 2017, Pages 751-757

  Fruhling P ^a   Nilsson, A ^a   Duraj, F ^a   Haglund, U ^a   Noren A ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Colorectal cancer; Interventional ultrasonography; Irreversible electroporation; Liver tumors

Indexed keywords

AMINOTRANSFERASE; MORPHINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILE DUCT DILATATION; CHOLESTASIS; CLINICAL ARTICLE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST-ENHANCED ULTRASOUND; DRAINAGE CATHETER; DYSPNEA; ELEVATED BLOOD PRESSURE; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEMATOMA; HUMAN; IRREVERSIBLE ELECTROPORATION ABLATION; LENGTH OF STAY; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER TUMOR; MALE; MELANOMA; MICROWAVE THERMOTHERAPY; MIDDLE AGED; PAIN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOFREQUENCY ABLATION; RECURRENCE RISK; SAFETY; TUMOR ABLATION; TUMOR RECURRENCE; TUMOR VOLUME; ABLATION THERAPY; BLOOD; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; COLORECTAL TUMOR; DIAGNOSTIC IMAGING; ECHOGRAPHY; ELECTROPORATION; LIVER NEOPLASMS; PATHOLOGY; POSTOPERATIVE COMPLICATIONS; PROCEDURES; SECONDARY; TREATMENT OUTCOME; X-RAY COMPUTED TOMOGRAPHY;

ABLATION TECHNIQUES; ADULT; AGED; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; CARCINOMA, HEPATOCELLULAR; COLORECTAL NEOPLASMS; ELECTROPORATION; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; ULTRASONOGRAPHY;

EID: 85009727854     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2016.12.004     Document Type: Article

References (32)

1. 1 Cummings, L.C., Payes, J.D., Cooper, G.S., Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer 109:4 (2007), 718–726.
2. 2 European Association for Study of L, European Organisation for R, Treatment of C, EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer 48:5 (2012), 599–641.
3. 3 Crocetti, L., de Baere, T., Lencioni, R., Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Interv Radiol 33:1 (2010), 11–17.
4. 4 Chu, K.F., Dupuy, D.E., Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer 14:3 (2014), 199–208.
5. 5 Davalos, R.V., Mir, L.M., Rubinsky, B., Tissue ablation with irreversible electroporation. Ann Biomed Eng 33:2 (2005), 223–231.
6. 6 Maor, E., Ivorra, A., Leor, J., Rubinsky, B., The effect of irreversible electroporation on blood vessels. Technol Cancer Res Treat 6:4 (2007), 307–312.
7. 7 Lee, E.W., Wong, D., Prikhodko, S.V., et al. Electron microscopic demonstration and evaluation of irreversible electroporation-induced nanopores on hepatocyte membranes. J Vasc Interv Radiol 23:1 (2012), 107–113.
8. 8 Lee, R.C., Cell injury by electric forces. Ann N Y Acad Sci 1066 (2005), 85–91.
9. 9 Lee, E.W., Loh, C.T., Kee, S.T., Imaging guided percutaneous irreversible electroporation: ultrasound and immunohistological correlation. Technol Cancer Res Treat 6:4 (2007), 287–294.
10. 10 Rubinsky, B., Onik, G., Mikus, P., Irreversible electroporation: a new ablation modality–clinical implications. Technol Cancer Res Treat 6:1 (2007), 37–48.
11. 11 Dollinger, M., Beyer, L.P., Haimerl, M., et al. Adverse effects of irreversible electroporation of malignant liver tumors under CT fluoroscopic guidance: a single-center experience. Diagn Interv Radiol 21:6 (2015), 471–475.
12. 12 Kingham, T.P., Karkar, A.M., D'Angelica, M.I., et al. Ablation of perivascular hepatic malignant tumors with irreversible electroporation. J Am Coll Surg 215:3 (2012), 379–387.
13. 13 Niessen, C., Igl, J., Pregler, B., et al. Factors associated with short-term local recurrence of liver cancer after percutaneous ablation using irreversible electroporation: a prospective single-center study. J Vasc Interv Radiol 26:5 (2015), 694–702.
14. 14 Sugimoto, K., Moriyasu, F., Kobayashi, Y., et al. Irreversible electroporation for nonthermal tumor ablation in patients with hepatocellular carcinoma: initial clinical experience in Japan. Jpn J Radiol 33:7 (2015), 424–432.
15. 15 Scheffer, H.J., Nielsen, K., van Tilborg, A.A., et al. Ablation of colorectal liver metastases by irreversible electroporation: results of the COLDFIRE-I ablate-and-resect study. Eur Radiol 24:10 (2014), 2467–2475.
16. 16 Scheffer, H.J., Nielsen, K., de Jong, M.C., et al. Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. J Vasc Interv Radiol 25:7 (2014), 997–1011 quiz.
17. 17 Niessen, C., Beyer, L.P., Pregler, B., et al. Percutaneous ablation of hepatic tumors using irreversible electroporation: a prospective safety and midterm efficacy study in 34 patients. J Vasc Interv Radiol 27:4 (2016), 480–486.
18. 18 Solbiati, L., Ierace, T., Tonolini, M., Cova, L., Guidance and monitoring of radiofrequency liver tumor ablation with contrast-enhanced ultrasound. Eur J Radiol 51 (2004), S19–S23.
19. 19 Lu, M.D., Yu, X.L., Li, A.H., et al. Comparison of contrast enhanced ultrasound and contrast enhanced CT or MRI in monitoring percutaneous thermal ablation procedure in patients with hepatocellular carcinoma: a multi-center study in China. Ultrasound Med Biol 33:11 (2007), 1736–1749.
20. 20 Piscaglia, F., Corradi, F., Mancini, M., et al. Real time contrast enhanced ultrasonography in detection of liver metastases from gastrointestinal cancer. BMC Cancer, 7, 2007, 171.
21. 21 Dietrich, C.F., Kratzer, W., Strobe, D., et al. Assessment of metastatic liver disease in patients with primary extrahepatic tumors by contrast-enhanced sonography versus CT and MRI. World J Gastroenterol 12:11 (2006), 1699–1705.
22. 22 Adeyanju, O.O., Al-Angari, H.M., Sahakian, A.V., The optimization of needle electrode number and placement for irreversible electroporation of hepatocellular carcinoma. Radiol Oncol 46:2 (2012), 126–135.
23. 23 Goldberg, S.N., Grassi, C.J., Cardella, J.F., et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol 20:7 Suppl. (2009), S377–S390.
24. 24 Ahmed, M., Solbiati, L., Brace, C.L., et al. Image-guided tumor ablation: standardization of terminology and reporting criteria–a 10-year update. Radiology 273:1 (2014), 241–260.
25. 25 Silk, M.T., Wimmer, T., Lee, K.S., et al. Percutaneous ablation of peribiliary tumors with irreversible electroporation. J Vasc Interv Radiol 25:1 (2014), 112–118.
26. 26 Narayanan, G., Bhatia, S., Echenique, A., Suthar, R., Barbery, K., Yrizarry, J., Vessel patency post irreversible electroporation. Cardiovasc Interv Radiol 37:6 (2014), 1523–1529.
27. 27 Thomson, K.R., Cheung, W., Ellis, S.J., et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol 22:5 (2011), 611–621.
28. 28 Cannon, R., Ellis, S., Hayes, D., Narayanan, G., Martin, R.C. 2nd, Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol 107:5 (2013), 544–549.
29. 29 Philips, P., Hays, D., Martin, R.C., Irreversible electroporation ablation (IRE) of unresectable soft tissue tumors: learning curve evaluation in the first 150 patients treated. PLoS One, 8(11), 2013, e76260.
30. 30 Froud, T., Venkat, S.R., Barbery, K.J., Gunjan, A., Narayanan, G., Liver function tests following irreversible electroporation of liver tumors: experience in 174 procedures. Tech Vasc Interv Radiol 18:3 (2015), 140–146.
31. 31 Granata, V., de Lutio di Castelguidone, E., Fusco, R., et al. Irreversible electroporation of hepatocellular carcinoma: preliminary report on the diagnostic accuracy of magnetic resonance, computer tomography, and contrast-enhanced ultrasound in evaluation of the ablated area. Radiol Med 121:2 (2016 Feb), 122–131.
32. 32 Narayanan, G., Froud, T., Suthar, R., Barbery, K., Irreversible electroporation of hepatic malignancy. Semin Interv Radiol 30:1 (2013), 67–73.